Peterlabs Holdings Bhd (XKLS:0171) EBIT: RM1.7 Mil (TTM As of Jun. 2025)


XKLS:0171 Peterlabs Holdings Bhd XKLS:0171
46 GF Score
Price RM0.24
GF Value RM0.20
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Peterlabs Holdings Bhd EBIT?

Peterlabs Holdings Bhd XKLS:0171 46 EBIT is RM1.7 Mil as of Jun. 2025. GuruFocus rates XKLS:0171 with a GF Score™ of 46/100 and a GF Value™ of RM0.20 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Peterlabs Holdings Bhd's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was RM-1.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was RM1.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Peterlabs Holdings Bhd's annualized ROC % for the quarter that ended in Jun. 2025 was -7.56%. Peterlabs Holdings Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -9.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Peterlabs Holdings Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 2.30%.

Peterlabs Holdings Bhd  (XKLS:0171) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Peterlabs Holdings Bhd's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-6.652 * ( 1 - 0% )/( (88.6 + 87.317)/ 2 )
=-6.652/87.9585
=-7.56 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=114.06 - 14.09 - ( 11.37 - max(0, 29.074 - 74.832+11.37))
=88.6

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=112.152 - 14.277 - ( 10.558 - max(0, 33.199 - 67.159+10.558))
=87.317

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Peterlabs Holdings Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.652/( ( (27.736 + max(41.476, 0)) + (34.022 + max(33.473, 0)) )/ 2 )
=-6.652/( ( 69.212 + 67.495 )/ 2 )
=-6.652/68.3535
=-9.73 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.13 + 28.727 + 0.70899999999999) - (14.09 + 0 + 3.5527136788005E-15)
=41.476

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24.17 + 22.585 + 1.222) - (14.277 + 0 + 0.227)
=33.473

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Peterlabs Holdings Bhd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=1.694/73.518
=2.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peterlabs Holdings Bhd EBIT Related Terms

Peterlabs Holdings Bhd EBIT Historical Data

* Premium members only.

The historical data trend for Peterlabs Holdings Bhd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peterlabs Holdings Bhd EBIT Chart

Peterlabs Holdings Bhd Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.23 5.71 9.27 5.03 6.19

Peterlabs Holdings Bhd Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.20 1.42 0.63 1.31 -1.66

XKLS:0171 vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Peterlabs Holdings Bhd EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Peterlabs Holdings Bhd's EV-to-EBIT falls into.


XKLS:0171
46GF Score
Peterlabs Holdings Bhd XKLS:0171
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Peterlabs Holdings Bhd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was RM1.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of RM1.7 Mil mean?
Peterlabs Holdings Bhd (XKLS:0171) has a EBIT of RM1.7 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Peterlabs Holdings Bhd.
Is Peterlabs Holdings Bhd's EBIT too high?
Peterlabs Holdings Bhd's current EBIT is RM1.7 Mil. Overall, Peterlabs Holdings Bhd has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's EBIT compare to ZTS and UTHR?
Peterlabs Holdings Bhd's EBIT of RM1.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Peterlabs Holdings Bhd. Peterlabs Holdings Bhd's current EBIT is RM1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 17.5% above its estimated fair value. The current EBIT is RM1.7 Mil. Peterlabs Holdings Bhd's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current EBIT is RM1.7 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?

Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued. The current stock price of RM0.24 is trading 17.5% above its estimated GF Value™ of RM0.20. GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.

Key valuation signals for XKLS:0171:

  • EBIT: RM1.7 Mil
  • GF Value™: RM0.20 vs. price of RM0.24 (17.5% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Peterlabs Holdings Bhd Business Description

Address Jalan Nilam 3, Lot 16014 (PT No. 24341), Bandar Nilai Utama, Nilai, NSN, MYS, 71800
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
46GF Score

Get the complete analysis for XKLS:0171

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.24
Price
RM0.20
GF Value